Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease

BACKGROUND: Registration authorities evaluate effects of new medicines for chronic obstructive pulmonary disease (COPD) on airway obstruction, dyspnea, health status and exacerbations. To establish clinical relevance, minimal clinically important differences (MCIDs) are used. The aim of this study w...

Full description

Saved in:
Bibliographic Details
Published in:Front Pharmacol
Main Authors: Dankers, Marloes, Nelissen-Vrancken, Marjorie H. J. M. G., Surminski, Sara M. K., Lambooij, Anke C., Schermer, Tjard R., van Dijk, Liset
Format: Artigo
Language:Inglês
Published: Frontiers Media S.A. 2020
Subjects:
Pharmacology
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7016298/
https://ncbi.nlm.nih.gov/pubmed/32116657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2019.01519
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items